Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide for NMIBC Chemoprevention
NCT02605863Phase 2Terminated
- Sponsor
- University of Rochester
- Start
- Jan 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of enzalutamide in Non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by University of Rochester. Primary endpoint: Number of Participants With Recurrent Disease at 1 year. Started Jan 2016; status: terminated.
02
Drugs
enzalutamide
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02605863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605863.